CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 58 enrolled
Drug / intervention
mirabegrondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02468830
NCT02468830Phase 3Completed

Prospective Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder

CHU de Quebec-Universite Laval·interventional·Posted Jun 11, 2015·Updated Jun 20, 2018

In Brief

A Phase 3 clinical trial evaluating mirabegron for Overactive Bladder and Urinary Incontinence. Completed, enrolled 58 participants.

Detailed Summary

The objective is to evaluate the efficacy and safety of mirabegron to treat urinary incontinence in children with Overactive Bladder that are refractory and/or intolerant to antimuscarinics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 11, 2015
Enrollment StartApr 1, 2013
Primary CompletionJan 1, 2016
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.1 years ago

Interventions

mirabegrondrug

Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.